Prostate Cancer Biomarker Articles & Analysis
4 news found
The biotech firm develops small molecules that target key proteins (called enzymes) in cancer. The company’s first candidate targets the prostate specific membrane antigen (PSMA) in prostate cancer, which is proposed to have both diagnostic and therapeutic applications. Two drugs are being developed, CTT1057 and CTT1403, ...
MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. ...
ByMiraDx
Cancer Targeted Technology (CTT) receives milestone payment for development of diagnostic PET imaging agent for prostate cancer. ...
This assay aims to provide deep analysis of the human plasma proteome for detection and characterization of novel prostate cancer biomarkers. If successful, clinical and research laboratories could use this assay to diagnose cancer and monitor the progress of treatment. If successful, the AP 3 -Assay will be expanded for ...